Sequential Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Induced Radical Surgery in Oligometastatic Non-small Cell Lung Cancer : A Case Report
© The Author(s) 2024. Published by Oxford University Press..
Sequential regimens in patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) can overcome tyrosine kinase inhibitor (TKI) resistance and maximize clinical benefit. Patients with advanced NSCLC can achieve excellent tumor control after a period of EGFR-TKI treatment. Patients may benefit from additional local treatment, such as surgery or radiation therapy, once the tumor is under control. Here, we present a case of a patient with advanced oligometastatic NSCLC with EGFR mutations who achieved downstaging through sequential EGFR-TKI-based precision medicine allowing resection of residual disease.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
The oncologist - (2024) vom: 10. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wang, Huaiyu [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Downstaging |
|---|
| Anmerkungen: |
Date Revised 11.01.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1093/oncolo/oyad339 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366949241 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366949241 | ||
| 003 | DE-627 | ||
| 005 | 20240114234106.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240114s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/oncolo/oyad339 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1256.xml |
| 035 | |a (DE-627)NLM366949241 | ||
| 035 | |a (NLM)38204337 | ||
| 035 | |a (PII)oyad339 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wang, Huaiyu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Sequential Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Induced Radical Surgery in Oligometastatic Non-small Cell Lung Cancer |b A Case Report |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 11.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © The Author(s) 2024. Published by Oxford University Press. | ||
| 520 | |a Sequential regimens in patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) can overcome tyrosine kinase inhibitor (TKI) resistance and maximize clinical benefit. Patients with advanced NSCLC can achieve excellent tumor control after a period of EGFR-TKI treatment. Patients may benefit from additional local treatment, such as surgery or radiation therapy, once the tumor is under control. Here, we present a case of a patient with advanced oligometastatic NSCLC with EGFR mutations who achieved downstaging through sequential EGFR-TKI-based precision medicine allowing resection of residual disease | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a EGFR L718Q | |
| 650 | 4 | |a downstaging | |
| 650 | 4 | |a oligometastatic NSCLC | |
| 650 | 4 | |a whole course medical management | |
| 700 | 1 | |a Fan, Zaiwen |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Xiaoming |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Qing |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Suxin |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Jingna |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Jie |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Chuanhong |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Yinghui |e verfasserin |4 aut | |
| 700 | 1 | |a You, Xia |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Yong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The oncologist |d 1998 |g (2024) vom: 10. Jan. |w (DE-627)NLM095483306 |x 1549-490X |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:10 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/oncolo/oyad339 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 10 |c 01 | ||